GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Humacyte Inc (NAS:HUMA) » Definitions » FCF Yield %

Humacyte (Humacyte) FCF Yield % : -7.71 (As of Jun. 01, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Humacyte FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Humacyte's Trailing 12-Month Free Cash Flow is $-83.53 Mil, and Market Cap is $889.56 Mil. Therefore, Humacyte's FCF Yield % for today is -7.71%.

The historical rank and industry rank for Humacyte's FCF Yield % or its related term are showing as below:

HUMA' s FCF Yield % Range Over the Past 10 Years
Min: -38.93   Med: 0   Max: 0
Current: -7.71


HUMA's FCF Yield % is ranked better than
63.31% of 1551 companies
in the Biotechnology industry
Industry Median: -14.23 vs HUMA: -7.71

Humacyte's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.


Humacyte FCF Yield % Historical Data

The historical data trend for Humacyte's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Humacyte FCF Yield % Chart

Humacyte Annual Data
Trend Dec20 Dec21 Dec22 Dec23
FCF Yield %
- -10.90 -33.14 -25.67

Humacyte Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.80 -31.23 -17.81 -26.09 -29.96

Competitive Comparison of Humacyte's FCF Yield %

For the Biotechnology subindustry, Humacyte's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Humacyte's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Humacyte's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Humacyte's FCF Yield % falls into.



Humacyte FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Humacyte's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-75.585 / 294.43416
=-25.67%

Humacyte's annualized FCF Yield % for the quarter that ended in Mar. 2024 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-27.738 * 4 / 370.35124
=-29.96%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Humacyte FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Humacyte FCF Yield % Related Terms

Thank you for viewing the detailed overview of Humacyte's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Humacyte (Humacyte) Business Description

Traded in Other Exchanges
N/A
Address
2525 East North Carolina Highway 54, Durham, NC, USA, 27713
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
Executives
Laura E Niklason director, 10 percent owner, officer: President, CEO and Director 35 WILSHIRE ROAD, GREENWICH CT 06831
Brady W Dougan director, 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Ayabudge Llc 10 percent owner 35 WILSHIRE ROAD, GREENWICH CT 06831
Heather Ledbetter Prichard officer: Chief Operating Officer 820 BROWNWICH STREET, WAKE FOREST NC 27587
Michael T. Constantino director C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615
Dale A. Sander officer: CFO & CCDO 11304 EMPIRE LAKES DRIVE, RALEIGH NC 27617
William John Scheessele officer: Chief Commercial Officer 620 WADE AVENUE, UNIT 501, RALEIGH NC 27605
Yang Cao officer: Chief Regulatory Officer 12 DOGLEG LANE, LAWRENCE NJ 08648
Charles Bruce Green director 3185 SCENIC DRIVE, NAPA CA 94558
Gordon M Binder director 225 S. LAKE AVE., SUITE 300, PASADENA CA 91101
Diane Seimetz director JUTASTRASSE, MUNICH 2M 80636
Shamik J Parikh officer: Chief Medical Officer 1160 HEDGEROW DRIVE, GARNET VALLEY PA 19060
Rajiv Shukla director EMERALD VIEW SUITE 400, 2054 VISTA PARKWAY, WEST PALM BEACH FL 33411
William Edward Tente officer: Chief Regulatory Officer 90 DAVIS STREET, SEEKONK MA 02771
Todd Pope director C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713

Humacyte (Humacyte) Headlines

From GuruFocus

Heather Prichard, COO of Humacyte Inc, Sells 23,402 Shares

By GuruFocus Research 05-28-2023

Insider Alert: An Insider Just Sold Humacyte Inc Shares

By GuruFocus Research GuruFocus Editor 12-20-2022

Humacyte First Quarter 2023 Financial Results and Business Update

By sperokesalga sperokesalga 05-12-2023